Skip to main content
. 2015 Apr 30;7(2):763–783. doi: 10.3390/cancers7020763

Figure 2.

Figure 2

Approximate proportion of crizotinib-resistant mechanisms [32,34]. ALK secondary mutations include 1151Tins, L1152R, C1156Y, F1174L, L1196M, G1202R, S1206Y, and G1269A.